Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Assets (2016 - 2025)

Historic Assets for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $1.5 billion.

  • Ascendis Pharma A's Assets rose 2030.96% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 2030.96%. This contributed to the annual value of $1.5 billion for FY2025, which is 1679.1% up from last year.
  • Per Ascendis Pharma A's latest filing, its Assets stood at $1.5 billion for Q4 2025, which was up 2030.96% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Assets ranged from a high of $2.3 billion in Q4 2021 and a low of $816.6 million during Q2 2024
  • Its 5-year average for Assets is $1.2 billion, with a median of $1.2 billion in 2021.
  • As far as peak fluctuations go, Ascendis Pharma A's Assets skyrocketed by 6973.81% in 2021, and later tumbled by 5135.94% in 2022.
  • Over the past 5 years, Ascendis Pharma A's Assets (Quarter) stood at $2.3 billion in 2021, then crashed by 51.36% to $1.1 billion in 2022, then decreased by 20.1% to $888.3 million in 2023, then surged by 41.89% to $1.3 billion in 2024, then rose by 20.31% to $1.5 billion in 2025.
  • Its Assets was $1.5 billion in Q4 2025, compared to $1.3 billion in Q3 2025 and $1.2 billion in Q2 2025.